In some aspects, the disclosure relates to single-arm AetRIIA heteromultimers and sing-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce tire progression rate and/or severity of renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.

In some aspects, the disclosure relates to single-arm AetRIIA heteromultimers and sing-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce tire progression rate and/or severity of renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.

In some aspects, the disclosure relates to single-arm AetRIIA heteromultimers and sing-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce tire progression rate and/or severity of renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.

The present invention is directed to a method for treating an IFN-γ associated disease or disorder in a subject in need thereof, including administering to the subject a pharmaceutical composition including a therapeutically effective amount of a compound capable of manipulating or modulating PD-L1 signaling or pathway.

The present invention is directed to a method for treating an IFN-γ associated disease or disorder in a subject in need thereof, including administering to the subject a pharmaceutical composition including a therapeutically effective amount of a compound capable of manipulating or modulating PD-L1 signaling or pathway.

Provided are compounds as defined by Formula 1 and uses thereof for the prevention or treatment of disease or conditions such as organ injury or organ failure.

Provided are compounds as defined by Formula 1 and uses thereof for the prevention or treatment of disease or conditions such as organ injury or organ failure.

Provided are improved methods for grafting donor derived CDS 4+ cells in an organ transplant recipient comprising administration CD3+ cells together with a calcineurin inhibitor in an effective amount to reduce or prevent an immune system of the recipient from rejecting the CD3+ cells from the donor, thereby enabling the CD3+ cells of the donor to facilitate engraftment of the CDS 4+ cells from the donor. In certain embodiments, the effective amount of the calcineurin inhibitor provided to reduce or prevent the immune system of the recipient from rejecting the CD3+ cells of the donor is lower than an amount provided for protecting the organ of the donor from rejection by the immune system of the recipient.

Provided are improved methods for grafting donor derived CDS 4+ cells in an organ transplant recipient comprising administration CD3+ cells together with a calcineurin inhibitor in an effective amount to reduce or prevent an immune system of the recipient from rejecting the CD3+ cells from the donor, thereby enabling the CD3+ cells of the donor to facilitate engraftment of the CDS 4+ cells from the donor. In certain embodiments, the effective amount of the calcineurin inhibitor provided to reduce or prevent the immune system of the recipient from rejecting the CD3+ cells of the donor is lower than an amount provided for protecting the organ of the donor from rejection by the immune system of the recipient.

Provided are improved methods for grafting donor derived CDS 4+ cells in an organ transplant recipient comprising administration CD3+ cells together with a calcineurin inhibitor in an effective amount to reduce or prevent an immune system of the recipient from rejecting the CD3+ cells from the donor, thereby enabling the CD3+ cells of the donor to facilitate engraftment of the CDS 4+ cells from the donor. In certain embodiments, the effective amount of the calcineurin inhibitor provided to reduce or prevent the immune system of the recipient from rejecting the CD3+ cells of the donor is lower than an amount provided for protecting the organ of the donor from rejection by the immune system of the recipient.